Evidence map›Paper›PMID 36509377›Full record

SynthesisClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2023

Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis.

Bradley J Langford, Jean-Paul R Soucy, Valerie Leung, Miranda So, Angela T H Kwan, Jacob S Portnoff, Silvia Bertagnolio, Sumit Raybardhan, Derek R MacFadden, Nick Daneman

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 2 pooled it
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 2 syntheses or guidelines pooled it, 217 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A Seven-Year Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  13. Article
  14. Monitoring the Burden ofAntibiotics (Basel, Switzerland) · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Pioneering strategies for overcoming bacterial drug resistance.Journal of microbiology (Seoul, Korea) · 2026
    Article
  19. Article
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 3 countries.

Bradley J LangfordPublic Health Ontario, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. Electronic address: brad.langford@gmail.com.
Jean-Paul R SoucyDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Valerie LeungPublic Health Ontario, Toronto, Ontario, Canada; Toronto East Health Network, Toronto, Ontario, Canada.
Miranda SoLeslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Angela T H KwanDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Jacob S PortnoffFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Silvia BertagnolioDepartment of Surveillance, Prevention and Control, Division of Antimicrobial Resistance, World Health Organization, Geneva, Switzerland.
Sumit RaybardhanNorth York General Hospital, Toronto, Ontario, Canada.
Derek R MacFaddenDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada.
Nick DanemanPublic Health Ontario, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Public Health Ontario · CAUniversity of Toronto · CANorth York General Hospital · CAOttawa Hospital · CASunnybrook Health Science Centre · CAUniversity of Ottawa · CAUniversity of Queensland · AUWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCOVID-19 and antimicrobial resistance (AMR) are two intersecting global public health crises.

objectiveWe aimed to describe the impact of the COVID-19 pandemic on AMR across health care settings. DATA SOURCE: A search was conducted in December 2021 in WHO COVID-19 Research Database with forward citation searching up to June 2022. STUDY ELIGIBILITY: Studies evaluating the impact of COVID-19 on AMR in any population were included and influencing factors were extracted. Reporting of enhanced infection prevention and control and/or antimicrobial stewardship programs was noted.

methodsPooling was done separately for Gram-negative and Gram-positive organisms. Random-effects meta-analysis was performed.

resultsOf 6036 studies screened, 28 were included and 23 provided sufficient data for meta-analysis. The majority of studies focused on hospital settings (n = 25, 89%). The COVID-19 pandemic was not associated with a change in the incidence density (incidence rate ratio 0.99, 95% CI: 0.67-1.47) or proportion (risk ratio 0.91, 95% CI: 0.55-1.49) of methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci cases. A non-statistically significant increase was noted for resistant Gram-negative organisms (i.e. extended-spectrum beta-lactamase, carbapenem-resistant Enterobacterales, carbapenem or multi-drug resistant or carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii, incidence rate ratio 1.64, 95% CI: 0.92-2.92; risk ratio 1.08, 95% CI: 0.91-1.29). The absence of reported enhanced infection prevention and control and/or antimicrobial stewardship programs initiatives was associated with an increase in gram-negative AMR (risk ratio 1.11, 95% CI: 1.03-1.20). However, a test for subgroup differences showed no statistically significant difference between the presence and absence of these initiatives (p 0.40).

conclusionThe COVID-19 pandemic may have hastened the emergence and transmission of AMR, particularly for Gram-negative organisms in hospital settings. But there is considerable heterogeneity in both the AMR metrics used and the rate of resistance reported across studies. These findings reinforce the need for strengthened infection prevention, antimicrobial stewardship, and AMR surveillance in the context of the COVID-19 pandemic.

Indexed as

COVID-19Methicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsCarbapenemsDrug Resistance, BacterialHumansAnti-Bacterial AgentsCarbapenemsAntibiotic resistanceAntimicrobial resistanceAntimicrobial stewardshipCOVID-19InfectionPrevention and control

Identifiers

PMID36509377
PMCPMC9733301
OpenAlexW4311908261

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.